Hi, Peter! So sorry I missed this question earlier and have been delayed in responding.
We’ve described in the above post what we know about R21 so far (see the second and third paragraphs from the end). To summarize, R21 has been shown to have high efficacy in protecting against malaria, but it’s unclear to us so far how generalizable those results will be. R21 is also reportedly less complicated to manufacture, which could be helpful as demand for malaria vaccine is expected to outstrip supply—but we can’t independently verify this. We’ll keep monitoring the literature on R21, and we’ll consider any funding opportunities as they come up.
Thanks for this. Any thoughts or comments on the prospects of the new R21/Matrix-M malaria vaccine?
Hi, Peter! So sorry I missed this question earlier and have been delayed in responding.
We’ve described in the above post what we know about R21 so far (see the second and third paragraphs from the end). To summarize, R21 has been shown to have high efficacy in protecting against malaria, but it’s unclear to us so far how generalizable those results will be. R21 is also reportedly less complicated to manufacture, which could be helpful as demand for malaria vaccine is expected to outstrip supply—but we can’t independently verify this. We’ll keep monitoring the literature on R21, and we’ll consider any funding opportunities as they come up.
Best,
Miranda Kaplan
GiveWell Communications Associate